France Pneumococcal Vaccine Market

France Pneumococcal Vaccine Market Insights Forecasts to 2035

• The France Pneumococcal Vaccine Market Size Was Estimated at USD 145.2 Million in 2024
• The France Pneumococcal Vaccine Market Size is Expected to Grow at a CAGR of Around 13.1% from 2025 to 2035
• The France Pneumococcal Vaccine Market Size is Expected to Reach USD 562.2 Million by 2035

 

According to a research report published by Decision Advisor & Consulting, The France Pneumococcal Vaccine Market Size is Anticipated to reach USD 562.2 Million by 2035, Growing at a CAGR of 13.1% from 2025 to 2035. The France pneumococcal vaccine market is driven by government vaccination programs, growing awareness about disease prevention, and an increasing elderly population. Higher risk of pneumonia and strong healthcare support also encourage vaccine adoption.

 

Market Overview

The France pneumococcal vaccine market encompasses all activities related to the development, production, distribution, and administration of vaccines that prevent Streptococcus pneumoniae infections (pneumonia, meningitis, and bloodstream infections) in France. It involves the use of vaccines in the national immunization schedules for infants, adults, and other groups at high risk of such infections, which are mainly driven by disease prevention initiatives and vaccination programs supported by the government.

 

The France pneumococcal vaccine market is mainly influenced by the heavy burden of pneumococcal diseases that are especially common in older adults and other groups of people who are at risk. According to 2023 data, almost 6,000 cases of invasive pneumococcal disease were documented in France, among which a vast majority were adults aged 65 and over. This group is not only more prone to infection but also experiences higher severity and mortality from pneumococcal pneumonia. While infant vaccination is well-performed (coverage ~99.8%), the pneumococcal vaccine uptake among adults remains extremely low (approx. 5-17% of at-risk adults). Thus, there is an urgent need to increase protection in vulnerable populations, and, therefore, it is of great importance to expand the pneumococcal vaccine adoption.

 

The next steps for the France pneumococcal vaccine market consist of route and dosage changes, as well as higher vaccine adoption in older adults. Especially after the Haute Autorité de Santé's recommendation in 2025 to vaccinate all individuals aged 65 and over, thus making it easier for people to understand and follow the recommendations since they are no longer based on age and risk but consist of one group only. On the other hand, infant immunization programs in France are done in such a way that nearly all children are vaccinated against pneumococcal disease. Ongoing national surveillance and public health efforts contribute to the adult vaccine uptake. France's overall public health and vaccination plan is also very positive about the widening of adult immunization and other preventive measures by Santé publique France and the Ministry of Health's immunization plans. Thus, the government seems to be encouraging a broader pneumococcal vaccine adoption.

 

Report Coverage

This research report categorizes the market for the France pneumococcal vaccine market based on various segments and regions, and forecasts revenue growth and analyses trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the France pneumococcal vaccine market. Recent market developments and competitive strategies, such as expansion, product launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the France pneumococcal vaccine market.

 

Driving Factors

The France pneumococcal vaccine market is driven by the extensive prevalence of pneumococcal infections. The implementation of vaccination recommendations by the government, as well as the extension of the advice for adults aged 65 and over, favors a greater use of the vaccination. Besides that, a good number of long-term national immunization programs, a public healthcare system that covers the cost of the vaccine, and the rising consciousness of the importance of health promotion are still factors that contribute to the use of the pneumococcal vaccine in France.

 

Restraining Factors

The France pneumococcal vaccine market is restrained by factors such as low vaccination awareness and uptake among adults despite high risk, particularly in the elderly population. Vaccine hesitancy, limited routine adult immunization practices, and complexity in past vaccination guidelines have also been some of the reasons for the slower adoption. In addition, logistical challenges in outreach and follow-up for adult vaccination may limit market growth.

 

Market Segmentation

The France pneumococcal vaccine market share is classified into vaccine type, product, and end use.

• The pneumococcal conjugate vaccine segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France pneumococcal vaccine market is segmented by vaccine type into pneumococcal conjugate vaccine and pneumococcal polysaccharide vaccine. Among these, the pneumococcal conjugate vaccine segment accounted for the largest revenue market share in 2024 and is expected to grow at a significant CAGR during the forecast period. The pneumococcal conjugate vaccine segment is growing because it provides better and longer protection, especially for infants and older adults. It is widely recommended by the government and used in national vaccination programs in France. Recommendations and better clinical outcomes compared to polysaccharide vaccines.

 

• The Prevnar 13 segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period.

The France pneumococcal vaccine market is segmented by product into Prevnar 13, Synflorix, Pneumovax 23, VAXNEUVANCE, PNEUMOSIL, and others. Among these, the Prevnar 13 segment dominated the market in 2024 and is anticipated to grow at a substantial CAGR during the forecast period. The Prevnar 13 segment is growing because it is highly effective and widely trusted by doctors. It is strongly recommended in France’s vaccination programs and is easily available through the public healthcare system.

 

• The public sector segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. 

The France pneumococcal vaccine market is segmented by end use into public sector and private sector. Among these, the public sector segment accounted for the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. The public sector segment is growing because the government runs large vaccination programs and pays for vaccines through the public healthcare system. Free or reimbursed vaccines for infants and older adults increase public sector demand.

 

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the France pneumococcal vaccine market, along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborate analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

 

List of Key Companies

• Pfizer Inc.
• GlaxoSmithKline plc (GSK)
• Merck & Co., Inc. (MSD)
• Sanofi S.A.
• Serum Institute of India Pvt. Ltd.
• SK Bioscience
• Walvax Biotechnology Co., Ltd.
• Panacea Biotec Ltd.
• Beijing Minhai Biotechnology Co., Ltd.
• AxiCorp Pharma
• Orifarm Group
• EurimPharm Arzneimittel GmbH
• Others

 

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

 

Recent Developments:

• In December 2024, Sanofi and SK Bioscience entered into a new chapter of their collaboration in pneumococcal vaccines with an expanded agreement to develop, license, and commercialize next-generation PCVs for both pediatric and adult populations, reaffirming their commitment to fighting pneumococcal disease.

 

Market Segment

This study forecasts revenue at the France, regional, and country levels from 2020 to 2035. Decision Advisor has segmented the France pneumococcal vaccine market based on the below-mentioned segments:

 

France Pneumococcal Vaccine Market, By Vaccine Type

• Pneumococcal Conjugate Vaccine
• Pneumococcal Polysaccharide Vaccine

 

France Pneumococcal Vaccine Market, By Product

• Prevnar 13
• Synflorix
• Pneumovax 23
• VAXNEUVANCE
• PNEUMOSIL
• Others

 

France Pneumococcal Vaccine Market, By End Use

• Public Sector
• Private Sector

 

FAQ’s

1. What is the France pneumococcal vaccine market size in 2024?

The France pneumococcal vaccine market size was estimated at USD 145.2 million in 2024.

 

2. What is the projected market size of the France pneumococcal vaccine market by 2035?

The France pneumococcal vaccine market size is expected to reach USD 562.2 million by 2035.

 

3. What is the CAGR of the France pneumococcal vaccine market?

The France pneumococcal vaccine market size is expected to grow at a CAGR of around 13.1% from 2024 to 2035.

 

4. What are the key growth drivers of the France pneumococcal vaccine market?

The France pneumococcal vaccine market is driven by government vaccination programs, growing awareness about disease prevention, and an increasing elderly population. Higher risk of pneumonia and strong healthcare support also encourage vaccine adoption.

 

5. Which product segment dominated the market in 2024?

The Prevnar 13 segment dominated the market in 2024.

 

6. What segments are covered in the France pneumococcal vaccine market report?

The France pneumococcal vaccine market is segmented on the basis of vaccine type, product, and end use.

 

7. Who are the key players in the France pneumococcal vaccine market?

Key companies include Pfizer Inc., GlaxoSmithKline plc (GSK), Merck & Co., Inc. (MSD), Sanofi S.A., Serum Institute of India Pvt. Ltd., SK Bioscience, Walvax Biotechnology Co., Ltd., Panacea Biotec Ltd., Beijing Minhai Biotechnology Co., Ltd., AxiCorp Pharma, Orifarm Group, EurimPharm Arzneimittel GmbH, and others.

 

8. Who are the target audiences for this market report?

The report targets market players, investors, end-users, government authorities, consulting and research firms, venture capitalists, and value-added resellers (VARs).